MX2021002543A - Proceso para la preparacion de composiciones de vacunas. - Google Patents

Proceso para la preparacion de composiciones de vacunas.

Info

Publication number
MX2021002543A
MX2021002543A MX2021002543A MX2021002543A MX2021002543A MX 2021002543 A MX2021002543 A MX 2021002543A MX 2021002543 A MX2021002543 A MX 2021002543A MX 2021002543 A MX2021002543 A MX 2021002543A MX 2021002543 A MX2021002543 A MX 2021002543A
Authority
MX
Mexico
Prior art keywords
disclosure
relates
polypeptides
inducing
pharmaceutical compositions
Prior art date
Application number
MX2021002543A
Other languages
English (en)
Inventor
Levente Molnár
József Toth
Orsolya Lorincz
Zsolt Csiszovszki
Eszter Somogyi
Katalin Pántya
Mónika Megyesi
Eniko Toke
Julianna Liszewicz
Péter Páles
Original Assignee
Treos Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Treos Bio Ltd filed Critical Treos Bio Ltd
Publication of MX2021002543A publication Critical patent/MX2021002543A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a polipéptidos, ácidos polinucleicos y composiciones farmacéuticas que comprenden polipéptidos que encuentran uso en la prevención o el tratamiento del cáncer. La invención también se refiere a métodos para inducir una respuesta de linfocitos T citotóxicos en un sujeto o para tratar el cáncer mediante la administración de composiciones farmacéuticas que comprenden los péptidos y métodos de diagnóstico complementarios. La invención también se refiere a un método para preparar un péptido o ácido polinucleico para su uso en un método para inducir una respuesta de linfocitos T contra un polipéptido diana; donde el método comprende identificar epítopos en el antígeno que se unen a múltiples alelos HLA de la mayor proporción de sujetos en una población objetivo.
MX2021002543A 2018-09-04 2019-09-03 Proceso para la preparacion de composiciones de vacunas. MX2021002543A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1814362.8A GB201814362D0 (en) 2018-09-04 2018-09-04 Composition and process for preparing vaccine
PCT/EP2019/073481 WO2020048995A1 (en) 2018-09-04 2019-09-03 Process for preparing vaccine compositions

Publications (1)

Publication Number Publication Date
MX2021002543A true MX2021002543A (es) 2021-08-11

Family

ID=63920945

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002543A MX2021002543A (es) 2018-09-04 2019-09-03 Proceso para la preparacion de composiciones de vacunas.

Country Status (17)

Country Link
US (3) US20200069786A1 (es)
EP (1) EP3847185A1 (es)
JP (1) JP2021535749A (es)
KR (1) KR20210086610A (es)
CN (1) CN113383009A (es)
AU (1) AU2019334261A1 (es)
BR (1) BR112021004075A2 (es)
CA (1) CA3110923A1 (es)
CL (1) CL2021000534A1 (es)
CO (1) CO2021004028A2 (es)
EA (1) EA202190669A1 (es)
GB (1) GB201814362D0 (es)
IL (1) IL281220A (es)
MA (1) MA53544A (es)
MX (1) MX2021002543A (es)
SG (1) SG11202101881UA (es)
WO (1) WO2020048995A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018158456A1 (en) 2017-03-03 2018-09-07 Treos Bio Zrt Personalised immunogenic peptide identification platform
GB201804468D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy PeptiCRAd Cancer Therapy
MA53543A (fr) 2018-09-04 2021-07-14 Treos Bio Ltd Vaccins peptidiques
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine
WO2021243295A2 (en) * 2020-05-29 2021-12-02 Children's National Medical Center Identification of hla-restricted prame peptide epitopes, prame-specific t cells suitable for "off-the-shelf" treatment of cancer expressing prame
CN111617238B (zh) * 2020-06-02 2022-12-13 苏州药明康德新药开发有限公司 小鼠ct26结直肠癌治疗性肿瘤多肽疫苗制剂及其制备方法
EP3945320A1 (en) * 2020-07-29 2022-02-02 Corporació Sanitària Parc Taulí Improved epitope for detecting and/or quantifying autoantibodies against alpha-fetoprotein
CA3196679A1 (en) * 2020-10-28 2022-05-05 Jan Alenfall Peptides for use in skin and hair pigmentation
CN113144181B (zh) * 2021-04-20 2022-07-19 徐州医科大学 一种靶向b7h3的dna疫苗、制备方法及应用
CN114195861A (zh) * 2022-01-05 2022-03-18 许昌学院 亲和肽
CN115785204B (zh) * 2022-06-10 2024-02-13 河北博海生物工程开发有限公司 肺癌特异性分子靶标08及其用途
CN115785211A (zh) * 2022-06-10 2023-03-14 河北博海生物工程开发有限公司 肺癌特异性分子靶标04及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
AUPQ776100A0 (en) * 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
GB0520067D0 (en) * 2005-10-01 2005-11-09 Cancer Rec Tech Ltd Treatment of cancer
WO2012051282A2 (en) * 2010-10-14 2012-04-19 The Ohio State University Research Foundation Piwil2-like (pl2l) proteins-targeted cancer diagnosis and therapy
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
EP3370065A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Immunogenic peptides
WO2018158456A1 (en) 2017-03-03 2018-09-07 Treos Bio Zrt Personalised immunogenic peptide identification platform
EP3369431A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Vaccine

Also Published As

Publication number Publication date
BR112021004075A2 (pt) 2021-05-25
US20210236611A1 (en) 2021-08-05
CL2021000534A1 (es) 2021-09-24
IL281220A (en) 2021-04-29
US20220160854A1 (en) 2022-05-26
JP2021535749A (ja) 2021-12-23
MA53544A (fr) 2021-07-14
KR20210086610A (ko) 2021-07-08
WO2020048995A1 (en) 2020-03-12
CA3110923A1 (en) 2020-03-12
EP3847185A1 (en) 2021-07-14
GB201814362D0 (en) 2018-10-17
CN113383009A (zh) 2021-09-10
AU2019334261A1 (en) 2021-03-18
CO2021004028A2 (es) 2021-06-21
SG11202101881UA (en) 2021-03-30
US20200069786A1 (en) 2020-03-05
EA202190669A1 (ru) 2021-06-03

Similar Documents

Publication Publication Date Title
MX2021002543A (es) Proceso para la preparacion de composiciones de vacunas.
MX2019010459A (es) Vacuna.
MX2022003884A (es) Tratamientos contra el cancer de utero.
MX2019006727A (es) Nuevos receptores de celulas t y terapia inmunologica que los utiliza.
EA201892021A1 (ru) Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний
EA201891759A1 (ru) Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний
EA202191027A2 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей
PE20240645A1 (es) Peptido inmunogenico derivado de moleculas de antigenos leucocitarios humanos (hla) como biomarcador en la inmunoterapia de diversos tumores
EA202190587A3 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака
EP3666793A3 (en) Combined t cell receptor gene therapy of cancer against mhc i and mhc ii-restricted epitopes of the tumor antigen ny-eso-1
PE20210517A1 (es) Anticuerpos anti-hla-g y utilizacion de los mismos
MX2023014457A (es) Peptidos antigenicos para la prevencion y el tratamiento del cancer.
MX2018003352A (es) Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer.
AU2021282532B2 (en) Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers
FI3463436T3 (fi) Rokote yhdistelmänä immuunivasteen tarkastuspisteen estäjän kanssa käytettäväksi hoidettaessa syöpää
MX2018010875A (es) Peptidos novedosos y combinacion de peptidos para usarse en inmunoterapia contra diferentes tumores.
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
CL2021000532A1 (es) Vacunas peptídicas
BR112019007028A2 (pt) métodos e composições farmacêuticas para o tratamento do câncer renal
EA202190186A1 (ru) Пептиды, комбинации пептидов и медикаменты на клеточной основе для применения в иммунотерапии рака мочевого пузыря и других видов рака
EA202190670A1 (ru) Пептидные вакцины
NZ746513A (en) Novel peptides and combination of peptides for use in immunotherapy against various tumors
PH12019501263A1 (en) Novel t cell receptors and immune therapy using the same
WO2020127996A8 (fr) Melanges d'epitopes t cd8+ immunogenes de la cycline b1
EA202190555A1 (ru) Рестриктированные по в*44 пептиды для применения в иммунотерапии раковых заболеваний и связанные с ними способы